MCL1 inhibitors
US12202842B2 · kind B2 · utility
0Cited by
5References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2023 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Mar 9, 2043 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.